Fat necrosis after accelerated partial breast irradiation or hypofractionated whole breast irradiation: A case-control study.

Partial breast irradiation case-control study fat necrosis whole breast irradiation

Journal

Tumori
ISSN: 2038-2529
Titre abrégé: Tumori
Pays: United States
ID NLM: 0111356

Informations de publication

Date de publication:
25 Oct 2024
Historique:
medline: 25 10 2024
pubmed: 25 10 2024
entrez: 25 10 2024
Statut: aheadofprint

Résumé

This study aimed to compare the incidence of fat necrosis after accelerated partial breast irradiation (APBI) vs hypofractionated whole breast irradiation (WBI) in patients with early-stage breast cancer. Data from early-stage breast cancer patients who underwent breast-conserving surgery and adjuvant radiotherapy between 2009 and 2022 were retrospectively collected. Radiation therapy consisted of APBI of 30 Gy in 5 daily fractions (Fx) (delivered in one week, consecutively) to the tumour bed or WBI (42.4 Gy in 16 Fx). Reports on fat necrosis were extracted from yearly mammograms and breast ultrasound imaging. The primary endpoint was the incidence of radiologically detected fat necrosis. A total of 536 patients were included among the APBI and WBI cohorts, with 268 and 268 patients respectively. The three-year Kaplan-Meier actuarial rate of fat necrosis was 32.8% (95% CI: 30.0% - 35.6%) for APBI and 22.3% (95% CI: 19.7% - 24.9%) for WBI patients. Univariate Kaplan-Meier survival analysis revealed a Hazard Ratio of 1.6 [95% CI: 1.1 - 2.2; p = 0.0055] for the fat necrosis rate within the APBI group compared to WBI. Multivariate Cox proportional hazard regression confirmed significant associations between fat necrosis and APBI (HR = 2.2 95% CI: 1.2 - 4.0; p = 0.01). The occurrence of radiologically diagnosed fat necrosis was higher in the APBI group compared to the WBI. Further investigations aiming to identify a lower-dose schedule with comparable efficacy to 30 Gy in 5 Fx but fewer toxicities, particularly for high-risk patients, are warranted.

Identifiants

pubmed: 39450849
doi: 10.1177/03008916241291305
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3008916241291305

Déclaration de conflit d'intérêts

Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Auteurs

Riccardo Ray Colciago (RR)

Department of Radiation Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
School of Medicine and Surgery, University of Milano Bicocca, Milano, Italy.

Eliana La Rocca (E)

Department of Radiation Oncology, Azienda Ospedaliero Universitaria Integrata, Verona, Italy.

Carlotta Giandini (C)

Department of Radiation Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Maria Grazia Carnevale (MG)

Department of Radiation Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Giulia Valeria Bianchi (GV)

Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Ilaria Maugeri (I)

Breast Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Catherine Depretto (C)

Breast Imaging Unit, Radiology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Silvia Meroni (S)

Medical Physics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Anna Cavallo (A)

Medical Physics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Emanuele Pignoli (E)

Medical Physics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Laura Lozza (L)

Department of Radiation Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Tiziana Rancati (T)

Data Science Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Maria Carmen De Santis (MC)

Department of Radiation Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Classifications MeSH